Journals / İstanbul Journal of Pharmacy / 2022 / Cilt: 52 - Sayı: 2

Obesogens: Definition, mechanisms of action, potential industrial chemicals and pharmaceuticals

Pages
215–225
Publication Date
2022-08-30
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this paper, we reviewed the mechanisms of obesogens, briefly overview several well-known obesogenic industrial chemicals and focused more on potential obesogenic pharmaceuticals.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The incidence of obesity and related diseases increased dramatically in the last decade.
📊
Key Findings & Data:Today, with the increased use of industrial chemicals, individuals are exposed to a mixture of chemicals at very low doses.
💡
Conclusion & Impact:In this paper, we reviewed the mechanisms of obesogens, briefly overview several well-known obesogenic industrial chemicals and focused more on potential obesogenic pharmaceuticals.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Endocrine disruptors · Obesogens · Adipogenesis

Abstract

The incidence of obesity and related diseases increased dramatically in the last decade. Some endocrine disruptors were shown to interact with metabolic processes via various cellular mechanisms, disrupt homeostasis in adipose tissue, resulting in weight gain and obesity. These chemicals are called “obesogens”. Today, with the increased use of industrial chemicals, individuals are exposed to a mixture of chemicals at very low doses. Most of these industrial chemicals have been investigated for their possible endocrine disrupting and obesogenic effects. Beside these chemicals, pharmaceuticals can also have similar adverse effects, however, limited studies have been performed to investigate such effects of drugs. Furthermore, there are few studies investigating the relationship between prenatal exposure to pharmaceuticals and childhood obesity. Therefore, to clarify the endocrine disrupting and obesogenic effects of the pharmaceuticals, which are prescribed during pregnancy, mechanistic studies should be performed, and necessary precautions should be taken. In this paper, we reviewed the mechanisms of obesogens, briefly overview several well-known obesogenic industrial chemicals and focused more on potential obesogenic pharmaceuticals.

🔖

Cite This Article

ENTEZARI, B., BOZDAĞ, D., GÜRER-ORHAN, H. (2022). Obesogens: Definition, mechanisms of action, potential industrial chemicals and pharmaceuticals. İstanbul Journal of Pharmacy, Cilt: 52 - Sayı: 2, 215–225. https://ajindex.com/articles/676212

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (7)

  1. Ahmed, S., & Atlas, E. (2016). Bisphenol S- and bisphenol A-in- duced adipogenesis of murine preadipocytes occurs through direct peroxisome proliferator-activated receptor gamma acti- vation. International Journal of Obesity (2005), 40(10), 1566–1573. https://doi.org/10.1038/IJO.2016.95
  2. Albaugh, V. L., Judson, J. G., She, P., Lang, C. H., Maresca, K. P., Joyal, J. L., & Lynch, C. J. (2011). Olanzapine promotes fat accumulation in male rats by decreasing physical activity, repartitioning energy and increasing adipose tissue lipogenesis while impairing lipolysis. Mo- lecular Psychiatry, 16(5), 569–581. https://doi.org/10.1038/MP.2010.33
  3. Albert, O., Desdoits-Lethimonier, C., Lesné, L., Legrand, A., Guillé, F., Bensalah, K., … Jégou, B. (2013). Paracetamol, aspirin and in- domethacin display endocrine disrupting properties in the adult human testis in vitro. Human Reproduction (Oxford, England), 28(7), 1890–1898. https://doi.org/10.1093/humrep/det112
  4. Alonso-Magdalena, P., Laribi, O., Ropero, A. B., Fuentes, E., Ripoll, C., Soria, B., & Nadal, A. (2005). Low doses of bisphenol A and di- ethylstilbestrol impair Ca2+ signals in pancreatic α-cells through a nonclassical membrane estrogen receptor within intact islets of Langerhans. Environmental Health Perspectives, 113(8), 969–977. https://doi.org/10.1289/ehp.8002
  5. Arterburn, D., Sofer, T., Boudreau, D., Bogart, A., Westbrook, E., Theis, M., … Haneuse, S. (2016). Long-Term Weight Change after Initiating Second-Generation Antidepressants. Journal of Clinical Medicine, 5(4), 48-60. https://doi.org/10.3390/jcm5040048
  6. Atli, O., Baysal, M., Aydogan-Kilic, G., Kilic, V., Ucarcan, S., Kara- duman, B., & Ilgin, S. (2017). Sertraline-induced reproductive toxicity in male rats: Evaluation of possible underlying mecha- nisms. Asian Journal of Andrology, 19(6), 672–679. https://doi. org/10.4103/1008-682X.192637 Autrup, H., Barile, F. A., Berry, S. C., Blaauboer, B. J., Boobis, A., Bolt, H., … Vermeulen, N. P. (2020). Human exposure to synthetic en- docrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable en- docrine activity. How to evaluate the risk of the S-EDCs? Toxicol- ogy in Vitro, 67, 104861. https://doi.org/10.1016/J.TIV.2020.104861
  7. Baillie-Hamilton, P. F. (2002). Chemical toxins: A hypothesis to explain the global obesity epidemic. Journal of Alterna- tive and Complementary Medicine, 8(2), 185–192. https://doi. org/10.1089/107555302317371479 Bashshur, R.